← Back to headlines
Agenus Stock Doubles Following Biotech's Narrowed Phase 3 Focus
Agenus stock experienced a significant surge, doubling in value, after the biotech company announced a narrowed focus for its Phase 3 clinical trials.
14 Jul, 14:17 — 14 Jul, 14:17
Sources
Showing 1 of 1 sources
